Assertio Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Assertio Therapeutics
ASRT Stock  USD 0.96  0.03  3.23%   
Assertio Therapeutics financial statements provide useful quarterly and yearly information to potential Assertio Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Assertio Therapeutics financial statements helps investors assess Assertio Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Assertio Therapeutics' valuation are summarized below:
Gross Profit
138.3 M
Profit Margin
(0.54)
Market Capitalization
81.8 M
Enterprise Value Revenue
0.3199
Revenue
125.8 M
There are currently one hundred twenty fundamental signals for Assertio Therapeutics that can be evaluated and compared over time across rivals. All traders should validate Assertio Therapeutics' prevailing fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Enterprise Value is likely to gain to about 1.6 B in 2024, whereas Market Cap is likely to drop slightly above 312.9 M in 2024.

Assertio Therapeutics Total Revenue

127.98 Million

Check Assertio Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Assertio Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 3.2 M, Total Revenue of 128 M or Gross Profit of 112.5 M, as well as many indicators such as Price To Sales Ratio of 0.47, Dividend Yield of 0.0 or PTB Ratio of 0.52. Assertio financial statements analysis is a perfect complement when working with Assertio Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Assertio Therapeutics Correlation against competitors.
For more information on how to buy Assertio Stock please use our How to Invest in Assertio Therapeutics guide.

Assertio Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets336.5 M286.4 M552 M
Very volatile
Short and Long Term Debt Total38.9 M40.9 M354.9 M
Pretty Stable
Total Current Liabilities72.3 M93.4 M116.3 M
Slightly volatile
Property Plant And Equipment Net1.9 M2 M6.2 M
Pretty Stable
Accounts Payable15.6 M13.4 M24.8 M
Very volatile
Non Current Assets Total203.4 M115.4 M354.4 M
Very volatile
Net Receivables26.3 M47.7 M41.5 M
Slightly volatile
Common Stock Shares Outstanding74.6 M71 M27.3 M
Slightly volatile
Liabilities And Stockholders Equity336.5 M286.4 M552 M
Very volatile
Other Current Assets25.5 M24.2 M19.7 M
Slightly volatile
Total Liabilities242.8 M148.4 M397.3 M
Very volatile
Total Current Assets133.1 M171.1 M197.7 M
Pretty Stable
Short Term Debt881.6 K928 K111.5 M
Pretty Stable
Cash80.2 M73.4 M126.2 M
Pretty Stable
Cash And Short Term Investments95.5 M73.4 M131.4 M
Pretty Stable
Non Current Liabilities Total52.2 M55 M273.1 M
Very volatile
Other Stockholder Equity829 M789.5 M303.8 M
Slightly volatile
Common Stock8.6 K9 K117.4 M
Slightly volatile
Other Assets0.951.027.9 M
Pretty Stable
Property Plant Equipment962.5 K1 M6.3 M
Pretty Stable
Common Stock Total Equity11.1 K11.7 K120.2 M
Slightly volatile
Property Plant And Equipment Gross5.7 M6.7 M6.9 M
Pretty Stable
Other Liabilities29.7 M23.8 M34.9 M
Pretty Stable
Inventory39.6 M37.7 M12.5 M
Slightly volatile
Long Term Investments229.1 K241.2 K12.9 M
Slightly volatile
Non Current Liabilities Other8.8 M9.2 M29.7 M
Pretty Stable
Capital Surpluse552.7 M526.4 M241.4 M
Slightly volatile
Deferred Long Term Asset Charges39.7 M20.7 M38.2 M
Slightly volatile
Long Term Debt Total402.2 M244.1 M359.8 M
Very volatile
Short and Long Term Debt401.9 K423 K181.6 M
Slightly volatile
Net Invested Capital317.3 M176.2 M577.8 M
Slightly volatile
Capital Stock6 K9 K6.6 K
Pretty Stable

Assertio Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue128 M152.1 M208.2 M
Very volatile
Gross Profit112.5 M125 M182.4 M
Very volatile
Other Operating Expenses415.4 M395.6 M227.2 M
Slightly volatile
Total Operating Expenses387 M368.6 M200.5 M
Slightly volatile
Depreciation And Amortization26.2 M28.2 M43.8 M
Pretty Stable
Selling General Administrative101.7 M65.3 M108.6 M
Pretty Stable
Selling And Marketing Expenses4.2 M4.4 M4.8 M
Slightly volatile
Interest Income51.4 M49 M50.5 M
Slightly volatile
Reconciled Depreciation49.4 M28.2 M81.3 M
Slightly volatile

Assertio Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow63.8 M64.9 M99.6 M
Very volatile
Depreciation26.9 M28.2 M45 M
Pretty Stable
Stock Based Compensation9.3 M9.2 M9 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.470.49985.0994
Slightly volatile
Days Sales Outstanding10911484.7664
Slightly volatile
Average Payables1.9 M2.9 M2.9 M
Pretty Stable
Stock Based Compensation To Revenue0.03560.06020.0452
Pretty Stable
Capex To Depreciation0.02110.02220.3787
Slightly volatile
EV To Sales0.270.28595.4069
Slightly volatile
Inventory Turnover0.680.7172.583
Very volatile
Days Of Inventory On Hand316509257
Pretty Stable
Sales General And Administrative To Revenue0.410.42970.5212
Pretty Stable
Average Inventory2.6 M3.5 M3.7 M
Very volatile
Research And Ddevelopement To Revenue0.02040.02150.1513
Slightly volatile
Capex To Revenue0.00390.00410.0256
Slightly volatile
Cash Per Share0.981.03399.5136
Slightly volatile
Intangibles To Total Assets0.420.38870.4764
Slightly volatile
Current Ratio3.41.83072.267
Pretty Stable
Receivables Turnover4.833.19055.6012
Slightly volatile
Graham Number16.2914.292826.1948
Slightly volatile
Capex Per Share0.00840.00880.2182
Pretty Stable
Average Receivables528.6 K333.7 K334.3 K
Very volatile
Revenue Per Share2.032.140911.7554
Pretty Stable
Interest Debt Per Share0.560.589820.8501
Very volatile
Debt To Assets0.130.13450.4089
Pretty Stable
Operating Cycle592623326
Pretty Stable
Long Term Debt To Capitalization0.340.21820.4692
Very volatile
Total Debt To Capitalization0.350.21820.4959
Very volatile
Quick Ratio1.361.42742.0327
Pretty Stable
Net Income Per E B T1.191.30661.7949
Very volatile
Cash Ratio0.750.78592.109
Slightly volatile
Days Of Inventory Outstanding316509257
Pretty Stable
Days Of Sales Outstanding10911484.7664
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.110.98730.9908
Very volatile
Fixed Asset Turnover78.3174.580257.2447
Slightly volatile
Debt Ratio0.130.13450.4089
Pretty Stable
Price Sales Ratio0.470.49985.0994
Slightly volatile
Asset Turnover0.280.53090.4021
Pretty Stable
Gross Profit Margin1.320.82230.943
Pretty Stable

Assertio Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap312.9 M481.4 M569.7 M
Very volatile
Enterprise Value1.6 B1.5 B1.3 B
Slightly volatile

Assertio Fundamental Market Drivers

Forward Price Earnings11.6686
Cash And Short Term Investments73.4 M

Assertio Upcoming Events

13th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Assertio Therapeutics Financial Statements

Assertio Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Assertio Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Assertio Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Assertio Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue77.5 M42 M
Total Revenue152.1 M128 M
Cost Of Revenue27 M20.2 M
Stock Based Compensation To Revenue 0.06  0.04 
Sales General And Administrative To Revenue 0.43  0.41 
Research And Ddevelopement To Revenue 0.02  0.02 
Revenue Per Share 2.14  2.03 
Ebit Per Revenue(1.60)(1.68)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Assertio Stock Analysis

When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY